Persistent B-cell depletion after rituximab for thrombocytopenic purpura

Eur J Pediatr. 2007 Jan;166(1):85-6. doi: 10.1007/s00431-006-0222-0. Epub 2006 Aug 3.

Author

Gianni Bisogno¹

Affiliation

¹ Division of Hematology/Oncology, Department of Pediatrics, University Hospital of Padova, Via Giustiniani 3, 35128 Padova, Italy. [email protected]

PMID: 16896642
DOI: 10.1007/s00431-006-0222-0

No abstract available

Publication types

Case Reports

MeSH terms

Adolescent
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Murine-Derived
B-Lymphocytes / drug effects*
Female
Humans
Immunoglobulins, Intravenous / therapeutic use
Immunologic Factors / administration & dosage
Immunologic Factors / adverse effects*
Immunologic Factors / therapeutic use
Platelet Count
Purpura, Thrombocytopenic / drug therapy*
Rituximab

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Immunoglobulins, Intravenous
Immunologic Factors
Rituximab